CXCR4 and myocardial infarction: HPβCD/Ang-(1–7) combination treatment ameliorates the post-infarction condition due to the modulation of proteins that initially favour the resolution of inflammation and mitochondrial dysfunctionAng-(1–7) treatment after experimental myocardial infarction leads to the downregulation of the C-X-C chemokine receptor type 4 (CXCR4)